When the GPR17-silencing cells were treated with PRT4165, the ROS levels or the viable cell numbers returned to similar levels as those in U87/U251-shScr cells, suggesting that the inhibitory effect of GPR17 on glioma development was mediated by PRC1-mediated histone monoubiquitination. The gene discussed is PRC1; the disease is central nervous system cancer.